Table 2. Genotype frequencies of XRCC1-rs25489 by mutation and disease status and hazard ratio estimates from stages I and II and combined.
| Genotype | Unaffected (%) | Affected (%) | HR | 95% CI | P-value | |
|---|---|---|---|---|---|---|
| Stage I | ||||||
| BRCA1 (n=701) | GG | 300 (89.8) | 317 (86.4) | 1.00 | ||
| AG | 33 (9.88) | 49 (13.4) | 1.29 | 0.85–1.97 | 0.2 | |
| AA | 1 (0.30) | 1 (0.27) | 0.87 | 0.24–3.20 | 0.8 | |
| BRCA2 (n=576) | GG | 226 (88.3) | 283 (88.4) | 1.00 | ||
| AG | 30 (11.7) | 35 (10.9) | 1.20 | 0.69–2.08 | 0.5 | |
| AA | 0 | 2 (0.63) | 22.3 | 14.6–34.0 | <0.001 | |
| Stage II | ||||||
| BRCA1 (n=4480) | GG | 1659 (89.5) | 1757 (91.2) | 1.00 | ||
| AG | 192 (10.4) | 166 (8.62) | 0.83 | 0.67–1.02 | 0.07 | |
| AA | 2 (0.11) | 3 (0.16) | 1.26 | 0.30–5.32 | 0.8 | |
| BRCA2 (n=3016) | GG | 1045 (89.9) | 1143 (89.2) | 1.00 | ||
| AG | 112 (9.64) | 131 (10.3) | 0.98 | 0.77–1.25 | 0.9 | |
| AA | 5 (0.43) | 4 (0.31) | 0.73 | 0.21–2.52 | 0.6 | |
| Combined | ||||||
| BRCA1 (n=5181) | GG | 1959 (89.6) | 2074 (90.5) | 1.00 | ||
| AG | 225 (10.3) | 215 (9.38) | 0.89 | 0.74–1.07 | 0.2 | |
| AA | 3 (0.14) | 4 (0.17) | 0.72 | 0.20–2.60 | 0.6 | |
| BRCA2 (n=3592) | GG | 1271 (89.6) | 1426 (89.2) | 1.00 | ||
| AG | 142 (10) | 166 (10.4) | 1.02 | 0.81–1.28 | 0.9 | |
| AA | 5 (0.35) | 6 (0.38) | 1.08 | 0.37–3.14 | 0.9 | |
Abbreviations: CI=confidence interval; HR=hazard ratio. Statistically significant results are highlighted in bold.